Chardan Capital Predicts Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Equities researchers at Chardan Capital issued their FY2025 earnings estimates for shares of Prothena in a research note issued to investors on Monday, March 24th. Chardan Capital analyst R. Li anticipates that the biotechnology company will post earnings per share of ($3.25) for the year. Chardan Capital currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). The firm had revenue of $2.12 million during the quarter, compared to analyst estimates of $7.53 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%.

PRTA has been the subject of several other research reports. Royal Bank of Canada lowered their price target on Prothena from $24.00 to $20.00 and set a “sector perform” rating for the company in a report on Friday, February 21st. Piper Sandler lifted their target price on shares of Prothena from $94.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and set a $48.00 price objective on shares of Prothena in a research note on Friday, February 21st. Finally, Bank of America cut their target price on Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Thursday, December 19th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Prothena Price Performance

Prothena stock opened at $13.01 on Thursday. The business has a fifty day moving average price of $14.33 and a 200-day moving average price of $15.66. Prothena has a 1-year low of $11.70 and a 1-year high of $26.36. The stock has a market capitalization of $700.29 million, a price-to-earnings ratio of -5.66 and a beta of -0.02.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC raised its stake in shares of Prothena by 19.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 833 shares during the last quarter. Headlands Technologies LLC raised its position in Prothena by 196.5% during the fourth quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 4,858 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in Prothena during the fourth quarter valued at approximately $145,000. Purkiss Capital Advisors LLC acquired a new position in Prothena in the fourth quarter valued at approximately $149,000. Finally, Chicago Partners Investment Group LLC purchased a new stake in Prothena in the 4th quarter worth approximately $159,000. 97.08% of the stock is currently owned by institutional investors and hedge funds.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.